Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are ...

Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...